The U.S. proton therapy market is expected to reach $1 billion in revenues by 2022, growing at a compound annual growth rate of more than 16%, according to a new report from Research and Markets.
By that time, the U.S. will have 38 proton therapy centers, the company predicted.
Access to proton therapy has been limited, due to a low number of proton therapy centers and insurance coverage barriers. But as more hospitals invest in proton therapy and insurance coverage improves -- the technology is now covered by Medicare -- the use of proton therapy is expected to increase, Research and Markets said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
